Latest News

FDA approves pegcetacoplan as first treatment for C3 glomerulopathy or IC-MPGN | Image credit: Contemporary Pediatrics
FDA approves pegcetacoplan as first treatment for C3 glomerulopathy or IC-MPGN

July 29th 2025

Pegcetacoplan (Empaveli: Apellis PHarmaceuticals) is indicated for patients aged 12 years and older to reduce proteinuria.

WATCH: Experts react to the FDA approval of sepiapterin to treat PKU
WATCH: Experts react to the FDA approval of sepiapterin to treat PKU

July 29th 2025

FDA approves sepiapterin to treat phenylketonuria in adult, pediatric patients
FDA approves sepiapterin to treat phenylketonuria in adult, pediatric patients

July 29th 2025

FDA approves avatrombopag for pediatric immune thrombocytopenia, including new sprinkle formulation | Image credit: Contemporary Pediatrics
FDA approves avatrombopag for pediatric immune thrombocytopenia, including new sprinkle formulation

July 28th 2025

Study: Daily emollient for infants could reduce atopic dermatitis incidence | Image credit: stock.adobe.com.
Study: Daily emollient for infants could reduce atopic dermatitis incidence

July 28th 2025

Latest Videos
Podcasts

All News

© 2025 MJH Life Sciences

All rights reserved.